Single-agent gemcitabine in patients with resistant small-cell lung cancer.
| Autor: | van der Lee I; Department of Pulmonology, St. Antonius Hospital, Nieuwegein, The Netherlands., Smit EF, van Putten JW, Groen HJ, Schlösser NJ, Postmus PE, Schramel FM |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2001 Apr; Vol. 12 (4), pp. 557-61. |
| DOI: | 10.1023/a:1011104509759 |
| Abstrakt: | Objective: This study was conducted to assess the activity and toxicity ofgemcitabine in patients with resistant small-cell lung cancer (SCLC). PATIENTS TAND METHODS: Forty-one patients with limited- or extensive-stage SCLC, who were previously treated with at least one chemotherapeutic regimen and progressed during or within three months of finishing the last regimen, were treated with 1000 mg/m2 gemcitabine on days 1, 8, and 15 of a four-week cycle. Results: Thirty-eight patients were evaluable for response. Five partial and no complete responses were seen, for an overall response rate of 13% (95% confidence interval (CI): 6%-27%). Time to progression varied from 4 to 20 weeks, with a median of 8 weeks. Median survival was 17 weeks (range 4-84 weeks). Hematological toxicity mainly consisted of NCI-CTC grade 3 thrombocytopenia (29% of patients) and, to a lesser extent, grade 3 leukopenia (18% of patients). Non-hematological toxicity was mild, with nausea being the most commonly reported event. Conclusions: Gemcitabine has modest activity in patients with resistant SCLC. There is some non-cross resistance to most agents against SCLC. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|